Anti-tumor activity of arjunolic acid against Ehrlich Ascites Carcinoma cells in vivo and in vitro through blocking TGF-β type 1 receptor

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 28-34

  Elsherbiny, Nehal M ^a   Al Gayyar, Mohammed M H ^a,b  

^a MANSOURA UNIVERSITY   (Egypt)

^b UNIVERSITY OF TABUK   (Saudi Arabia)

Author keywords

Arjunolic acid; Caspase 3; Interleukin (IL) 10; Latency associated peptide (LAP); Transforming growth factor (TGF) ; Transforming growth factor ; Tumor necrosis factor (TNF) ; Type 1 receptors (TGF R1)

Indexed keywords

ARJUNOLIC ACID; CASPASE 3; CISPLATIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; LATENCY ASSOCIATED PEPTIDE; NATURAL PRODUCT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTACOID; MALONALDEHYDE; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARK; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; EHRLICH ASCITES TUMOR; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SWISS WEBSTER MOUSE; TERMINALIA ARJUNA; TUMOR VOLUME; ANIMAL; ASCITES; BIOLOGICAL MODEL; CARCINOMA, EHRLICH TUMOR; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCITES; CARCINOMA, EHRLICH TUMOR; CASPASE 3; CYTOKINES; FEMALE; INFLAMMATION MEDIATORS; MALONDIALDEHYDE; MICE; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRITERPENES;

EID: 84966415522     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.04.046     Document Type: Article

References (36)

1. Patt H.M., Straube R.L. Measurement and nature of ascites tumor growth. Ann. N. Y. Acad. Sci. 1956, 63(5):728-737.
2. Bromberg N., Dreyfuss J.L., Regatieri C.V., Palladino M.V., Durán N., Nader H.B., Haun M., Justo G.Z. Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem. Biol. Interact. 2010, 186(1):43-52.
3. Jaganathan S.K., Mondhe D., Wani Z.A., Pal H.C., Mandal M. Effect of honey and eugenol on Ehrlich ascites and solid carcinoma. J. Biomed. Biotechnol. 2010, 2010:989163.
4. Oršolić N., Car N., Lisičić D., Benković V., Knežević A.H., Dikić D., Petrik J. Synergism between propolis and hyperthermal intraperitoneal chemotherapy with Cisplatin on ehrlich ascites tumor in mice. J. Pharm. Sci. 2013, 102(12):4395-4405.
5. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73(9):994-1007.
6. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 2014:149185.
7. Bayomi H.S., Elsherbiny N.M., El-Gayar A.M., Al-Gayyar M.M. Evaluation of renal protective effects of inhibiting TGF-β type I receptor in a Cisplatin-induced nephrotoxicity model. Eur. Cytokine Netw. 2013, 24(4):139-147.
8. Nagaraj N.S., Datta P.K. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin. Investig. Drugs 2010, 19(1):77-91.
9. Elliott R.L., Blobe G.C. Role of transforming growth factor Beta in human cancer. J. Clin. Oncol. 2005, 23(9):2078-2093.
10. Sherif I.O., Al-Gayyar M.M. Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite. Eur. Cytokine Netw. 2013, 24(3):114-121.
11. Al-Gayyar M.M., AlYoussef A., Sherif I.O., Shams M.E., Abbas A. Protective effects of arjunolic acid against cardiac toxicity induced by oral sodium nitrite: effects on cytokine balance and apoptosis. Life Sci. 2014, 111(1-2):18-26.
12. Ghosh J., Das J., Manna P., Sil P.C. Acetaminophen induced renal injury via oxidative stress and TNF-alpha production: therapeutic potential of arjunolic acid. Toxicology 2010, 268(1-2):8-18.
13. Manna P., Sil P.C. Arjunolic acid: beneficial role in type 1 diabetes and its associated organ pathophysiology. Free Radic. Res. 2012, 46(7):815-830.
14. Ghosh J., Sil P.C. Arjunolic acid: a new multifunctional therapeutic promise of alternative medicine. Biochimie 2013, 95(6):1098-1109.
15. Ramesh A.S., Christopher J.G., Radhika R., Setty C.R., Thankamani V. Isolation, characterisation and cytotoxicity study of arjunolic acid from Terminalia arjuna. Nat. Prod. Res. 2012, 26(16):1549-1552.
16. Masoko P., Picard J., Howard R.L., Mampuru L.J., Eloff J.N. In vivo antifungal effect of Combretum and Terminalia species extracts on cutaneous wound healing in immunosuppressed rats. Pharm. Biol. 2010, 48(6):621-632.
17. El-Mesery M., Al-Gayyar M., Salem H., Darweish M., El-Mowafy A. Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div. 2009, 4:6.
18. Al-Gayyar M.M., Matragoon S., Pillai B.A., Ali T.K., Abdelsaid M.A., El-Remessy A.B. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes. Diabetologia 2011, 54(3):669-680.
19. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 1978, 90(1):37-43.
20. Somasagara R.R., Hegde M., Chiruvella K.K., Musini A., Choudhary B., Raghavan S.C. Extracts of strawberry fruits induce intrinsic pathway of apoptosis in breast cancer cells and inhibits tumor progression in mice. PLoS One 2012, 7(10):47021.
21. Sánchez-Pérez Y., Carrasco-Legleu C., García-Cuellar C., Pérez-Carreón J., Hernández-García S., Salcido-Neyoy M., Alemán-Lazarini L., Villa-Treviño S. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett. 2005, 217(1):25-32.
22. Al-Gayyar M.M., Elsherbiny N.M. Contribution of TNF-α to the development of retinal neurodegenerative disorders. Eur. Cytokine Netw. 2013, 24(1):27-36.
23. Salzman R., Pácal L., Tomandl J., Kanková K., Tóthová E., Gál B., Kostrica R., Salzman P. Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer. Anticancer Res. 2009, 29(10):4227-4231.
24. Manna P., Sil P.C. Impaired redox signaling and mitochondrial uncoupling contributes vascular inflammation and cardiac dysfunction in type 1 diabetes: protective role of arjunolic acid. Biochimie 2012, 94(3):786-797.
25. Sinha M., Manna P., Sil P.C. Arjunolic acid attenuates arsenic-induced nephrotoxicity. Pathophysiology 2008, 15(3):147-156.
26. Manna P., Sinha M., Sil P.C. Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch. Toxicol. 2008, 82(3):137-149.
27. Kubiczkova L., Sedlarikova L., Hajek R., Sevcikova S. TGF-β-an excellent servant but a bad master. J. Transl. Med. 2012, 10:183.
28. Connolly E.C., Freimuth J., Akhurst R.J. Complexities of TGF-β targeted cancer therapy. Int. J. Biol. Sci. 2012, 8(7):964-978.
29. Boudreau H.E., Casterline B.W., Burke D.J., Leto T.L. Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells. Br. J. Cancer 2014, 110(10):2569-2582.
30. Dzieran J., Fabian J., Feng T., Coulouarn C., Ilkavets I., Kyselova A., Breuhahn K., Dooley S., Meindl-Beinker N.M. Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines. PLoS One 2013, 8(8):72252.
31. Liu J., Liao S., Diop-Frimpong B., Chen W., Goel S., Naxerova K., Ancukiewicz M., Boucher Y., Jain R.K., Xu L. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(41):16618-16623.
32. Halder S.K., Beauchamp R.D., Datta P.K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005, 7(5):509-521.
33. Park C.Y., Min K.N., Son J.Y., Park S.Y., Nam J.S., Kim D.K., Sheen Y.Y. A novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett. 2014, 351(1):72-80.
34. Hamsa T.P., Kuttan G. Evaluation of the anti-inflammatory and anti-tumor effect of Ipomoea obscura (L) and its mode of action through the inhibition of proinflammatory cytokines, nitric oxide and COX-2. Inflammation 2011, 34(3):171-183.
35. Ghoneum M., Badr El-Din N.K., Noaman E., Tolentino L. Saccharomyces cerevisiae, the Baker's Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice. Cancer Immunol. Immunother. 2008, 57(4):581-592.
36. McIlwain D.R., Berger T., Mak T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013, 5(4):008656.